Pfizer Inc. (PFE)
This 7% Yielder Could Be a Top AI Play
A looming patent cliff in which Pfizer will lose patent exclusivity to a handful of drugs has combined with cratering revenue from COVID-19 treatments to drive Pfizer shares down 50% since 2022. Pfizer has two important catalysts that can help it not only survive but also thrive amid these these challenges.
Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters
Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in the obesity market, though the deal will be dilutive to earnings through 2030. Recent FDA approval of the PADCEV/Keytruda combination and a robust oncology pipeline are expected to drive future revenue and margin expansion.
Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December
This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Most of the dividend increases announced in the last two weeks of November were in the low-to-mid single-digit percentages, including a 5% boost from Merck. My expectations are high for December's increases, with at least five companies announcing 10%+ boosts, including Mastercard.
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
Pfizer Crosses Below Key Moving Average Level
In trading on Thursday, shares of Pfizer crossed below their 200 day moving average of $24.58, changing hands as low as $24.28 per share. Pfizer shares are currently trading off about 1.6% on the day.
Pfizer: Is This Pharma Giant Finally A Bargain
Following Pfizer's victory over Novo Nordisk in the "war" for Metsera, its stock resumed its upward momentum. But before the deal was completed, it again beat Wall Street analysts' consensus EPS and revenue estimates by a wide margin. Lorbrena, an ALK inhibitor against non-small cell lung cancer, brought in $268 million for Pfizer in Q3, up 30.1% year-on-year.
Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript
Pfizer Inc. ( PFE ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants David Denton - Executive VP & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good morning, everyone. I hope you're all doing well.
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
Activist Starboard sells Pfizer stake after pushing for changes
Activist investor Starboard Value has liquidated its position in Pfizer , according to a regulatory filing on Friday, ending its push for changes aimed at boosting the drugmaker's share price.
Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript
Pfizer Inc. ( PFE ) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Jeff Legos Johanna Bendell - Chief Development Officer of Oncology Arati Rao Conference Call Participants Steve Scala - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equity Research Jiexian Zhuang - Leerink Partners LLC, Research Division Ethan Brown - JPMorgan Chase & Co, Research Division Presentation Operator Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded.
